• BAPTA-AM: Advanced Calcium Chelation Strategies for Synaptic

  2026-07-28

  Explore how BAPTA-AM, a cell-permeable calcium chelator, enables precise manipulation of intracellular calcium for advanced neurobiology and synaptic studies. This article provides a uniquely deep analysis, connecting assay design to recent breakthroughs in localized BDNF signaling.

• Fumagillin: Translational Bridges in Angiogenesis and Protoz

  2026-07-28

  This article explores the dual role of Fumagillin as a methionine aminopeptidase-2 inhibitor in both cancer and antiparasitic research, providing mechanistic insight, experimental validation, and strategic guidance for translational scientists. By integrating evidence from tumor and aquaculture models, it advances the conversation beyond conventional product descriptions.

• Propranolol in Essential Tremor: Neurophysiological Insights

  2026-07-27

  Explore how propranolol, a non-selective β-adrenergic receptor blocker, modulates neurophysiology in essential tremor through central and peripheral mechanisms. This article reveals new assay considerations and research strategies based on recent TMS findings, taking your cardiovascular and neuropsychiatric investigations beyond existing guides.

• EZ Cap™ Human PTEN mRNA: Precision Tools for Tumor Suppresso

  2026-07-27

  Unlock translational power in cancer and gene therapy research with EZ Cap™ Human PTEN mRNA. This guide delivers actionable workflows, troubleshooting gold, and practical insights from the latest innovations in mRNA-based tumor suppressor delivery.

• Alfuzosin HCl: Mechanistic Insights and Translational Impact

  2026-07-26

  This thought-leadership article explores the mechanistic underpinnings and translational research strategies surrounding Alfuzosin HCl, a selective α1 adrenoceptor antagonist, with a focus on its role in benign prostatic hyperplasia (BPH) research. Integrating recent advances in experimental design, clinical context, and product intelligence, the piece provides actionable guidance for researchers aiming to bridge the gap between bench and bedside.

• Technical Guide: AZD8055 for mTOR Pathway Inhibition Studies

  2026-07-25

  AZD8055 is a potent, selective mTOR inhibitor suitable for preclinical research dissecting mTORC1 and mTORC2 signaling, especially in cancer and metabolic models. It is not appropriate for studies requiring clinical efficacy endpoints or water-soluble compounds, and demands strict workflow execution for reproducibility.

• Liproxstatin-1 (SKU B4987): Reliable Ferroptosis Inhibition

  2026-07-24

  This article addresses common laboratory challenges in ferroptosis and cell viability research, using scenario-driven Q&A to illustrate how Liproxstatin-1 (SKU B4987) ensures reproducibility, sensitivity, and workflow compatibility. Readers will find evidence-backed guidance on protocol optimization and vendor selection, with direct links to validated data and product resources.

• Tetrandrine (SKU N1798): Reliable Solutions for Cell-Based A

  2026-07-24

  This article addresses real laboratory challenges in cell viability, proliferation, and cytotoxicity assays, showcasing how Tetrandrine (SKU N1798) provides reproducible, data-driven solutions. Through evidence-based scenario analysis, we detail best practices, protocol optimization, and vendor selection strategies, positioning Tetrandrine as a trusted research compound for robust experimental outcomes.

• CB-5083: Potent p97 Inhibitor for Protein Homeostasis Disrup

  2026-07-23

  CB-5083 is a selective, orally available p97 inhibitor that disrupts protein homeostasis by targeting the AAA ATPase p97, leading to tumor growth inhibition and induction of apoptosis in multiple cancer models. Its precise action and robust in vitro and in vivo benchmarks make it a key tool for oncology and multiple myeloma research. APExBIO supplies CB-5083 (SKU B6032), ensuring reliable sourcing for translational studies.

• Dual Mitophagy Activation by EE Mitigates Ischemia–Reperfusi

  2026-07-23

  This study demonstrates that an enriched environment (EE) confers neuroprotection against cerebral ischemia–reperfusion injury by activating dual mitophagy pathways mediated through the dopamine–H2S axis. The findings highlight a mechanistically novel cascade involving coordinated PINK1/parkin and HIF-1α/BNIP3L signaling, providing a foundation for future interventions targeting mitochondrial quality control in ischemic brain injury.

• TSPAN18-STIM1 Axis Drives Bone Metastasis in Prostate Cancer

  2026-07-22

  Zhou et al. (2023) identify TSPAN18 as a crucial stabilizer of STIM1, protecting it from TRIM32-mediated degradation and thereby promoting calcium influx, prostate cancer cell invasion, and bone metastasis. This mechanistic insight provides a rationale for targeting the TSPAN18-STIM1 pathway in advanced prostate cancer research.

• GLT-1 Upregulation Attenuates TBI via CB1-CREB Pathway Inhib

  2026-07-22

  This study reveals that increasing GLT-1 expression in mouse models of traumatic brain injury (TBI) reduces neuronal apoptosis and cognitive dysfunction by suppressing the CB1-CREB signaling pathway. The findings highlight a mechanistic link between endocannabinoid signaling, astrocytic glutamate transport, and neuroprotection, offering a potential therapeutic approach for memory impairment and secondary brain injury.

• VER 155008: HSP 70 Inhibitor Workflows for Cancer Research

  2026-07-21

  VER 155008, a potent adenosine-derived HSP 70 inhibitor, enables precision dissection of chaperone biology and apoptosis in cancer models. This guide delivers actionable protocols, troubleshooting tips, and comparative insights to maximize experimental reliability in apoptosis and proliferation assays.

• TaqI Restriction Endonuclease: Protocols, QC, and Troublesho

  2026-07-21

  TaqI Restriction Endonuclease (SKU K3053) is designed for rapid, sequence-specific DNA digestion in research workflows involving plasmid, PCR, or genomic DNA. It is best suited for molecular cloning, genotyping, and analytical protocols that require fast and reliable DNA cleavage, but is not intended for diagnostic or therapeutic applications.

• Anagliptin (SK-0403): Advanced Workflows for Vascular Mechan

  2026-07-20

  Anagliptin (SK-0403) is transforming diabetes and vascular research with its dual action: potent DPP-4 inhibition and direct modulation of Kv channels and SERCA pumps. This guide delivers actionable protocols, troubleshooting, and cross-domain insights to help researchers unlock reliable and reproducible results in metabolic and cardiovascular studies.

454 records 10/31 page Previous Next First page 上5页 678910 下5页 Last page